Delivery Order SPE2DB24D2010-SPE2DB25FAAXY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Vyvanse 10 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $15,024.87. This is a child contract with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) on August 15, 2025, with a ceiling value of $4,198.84. This firm fixed-price delivery order is set to be completed by August 18, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Vyvanse 50 mg capsules (100-count) under a firm fixed-price contract with a ceiling value of $5,192.54. The order, which is classified as a child contract under a larger indefinite delivery vehicle, carries an ultimate completion date of July 24, 2025. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAXYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026 that supports military healthcare systems globally. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare operations. The company's role under the DLA Troop Support Medical IDC encompasses supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This specific delivery order for Vyvanse, a controlled medication used in treating attention deficit hyperactivity disorder, supports the company's broader mission to provide essential pharmaceutical commodities to military and federal healthcare systems. The DLA is planning next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards, positioning AmerisourceBergen among the key vendors within this strategic procurement approach.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/25/25 |